Polycaprolactone Subcutaneous Implant

Kaohsiung, Taiwan

SciVision Biotech Inc., established in 2001, is a publicly listed company on the Taiwan Stock Exchange since 2013 (Stock Code: 1786). We specialize in the development and manufacturing of premium medical-grade hyaluronic acid products. At SciVision Biotech Inc., we take pride in our self-developed and patented technologies, including the Crosslinked Hyaluronic Acid Platform (CHAP) and auto cross-linking technology. Through these in-house innovations, we have achieved precise control over the characteristics of hyaluronic acid, setting a new industry standard. Our patented auto cross-linking technology represents a breakthrough that eliminates the need for chemical cross-linking agents, positioning SciVision as the only company in the world capable of producing medical-grade crosslinked hyaluronic acid products without adding chemicals. This unique capability allows us to offer a broad portfolio of cross-linking hyaluronic acid products with diverse forms and physical properties.